Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct 6;1(2):56-61.
doi: 10.1002/jgh3.12009. eCollection 2017 Oct.

Outcome and validation of a new clinically based staging system for predicting survival of perihilar cholangiocarcinoma patients

Passisd Laoveeravat  1 , Veeravich Jaruvongvanich  2 , Nicha Wongjarupong  1   3 , Sittikorn Linlawan  1 , Natthaporn Tanpowpong  4 , Chonlada Phathong  1 , Parkpoom Phatharacharukul  5 , Sombat Treeprasertsuk  1 , Rungsun Rerknimitr  1 , Roongruedee Chaiteerakij  1
Affiliations

Outcome and validation of a new clinically based staging system for predicting survival of perihilar cholangiocarcinoma patients

Passisd Laoveeravat et al. JGH Open. .

Abstract

Background and aim: Currently available staging systems for cholangiocarcinoma (CCA) are not applicable to patients with unresectable stage. A new clinical staging system for perihilar CCA (pCCA) subtype has been recently developed in a US cohort, with a good performance in predicting survival of all pCCA patients. We aimed to determine outcomes of pCCA patients and evaluate predictive performance of this staging system in an Asian population.

Methods: All 141 patients diagnosed with pCCA between 2003 and 2012 were identified. Clinical information was retrospectively abstracted. Patients were classified into four stages based on the new staging system. Survival predictors were analyzed using the Cox proportional hazard analysis.

Results: Of the 141 pCCA patients, 38 (27%), 101 (72%), and 2 (1%) received resection, palliative biliary drainage ± chemotherapy, and best supportive care, respectively. Survival predictors included resectable disease, tumor size, distant metastasis, and cancer antigen 19-9 ≥ 1000 U/mL. When classified by clinical stages, 13, 4, 99, and 25 patients were in stages I, II, III, and IV, with median survivals of 18.4, 7.3, 6.3, and 2.6 months; and hazard ratio (95% confidence interval) of 1.0 (reference), 1.7 (0.5-5.5), 3.2 (1.5-6.7), and 10.8 (4.6-25.0), respectively.

Conclusion: The clinical staging system has a limited performance in differentiating stage II pCCA patients from stage III patients in the Thai cohort. This can be due to differences in patient characteristics and treatment modalities between the Asian and White pCCA populations. However, the median survivals of patients with other stages are significantly different.

Keywords: bile duct cancer; cholangiocarcinoma; prognosis; staging system; treatment outcome.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Survival curves of perihilar cholangiocarcinoma patients classified by clinical staging.
Figure 2
Figure 2
Survival curves of resectable patients (a) and patients receiving palliative biliary drainage ± systemic chemotherapy (b).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States Part III: liver, biliary tract, and pancreas. Gastroenterology. 2009; 136: 1134–44. - PubMed
    1. Bergquist A, von Seth E. Epidemiology of cholangiocarcinoma. Best Pract. Res. Clin. Gastroenterol. 2015; 29: 221–32. - PubMed
    1. Khan SA, Davidson BR, Goldin RD et al Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012; 61: 1657–69. - PubMed
    1. Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies. J. Clin. Oncol. 2010; 28: 3531–40. - PMC - PubMed
    1. Nakeeb A, Pitt HA, Sohn TA et al Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann. Surg. 1996; 224: 463–73; discussion 473–5. - PMC - PubMed

LinkOut - more resources